Improved equation for estimating single-pool $K_t/V$ at higher dialysis frequencies

John T. Daugirdas¹, John Ken Leypoldt², Alp Akonur², Tom Greene³ and Thomas A. Depner⁴
the FHN Trial Group⁵

Correspondence and offprint requests to:
John T. Daugirdas; E-mail: jtdaugir@uic.edu

ABSTRACT

Rationale. To measure adequacy in patients dialyzed other than three times per week, guidelines recommend the use of ‘standard’ $K_t/V$, which commonly is estimated from treatment $K_t/V$, time and frequency; however, the accuracy of equations that predict treatment $K_t/V$ in patients being dialyzed other than three times per week has not been evaluated.

Methods. In patients enrolled in the Frequent Hemodialysis Network (FHN) Daily and Nocturnal Trials who were being dialyzed three, four or six times per week, we tested the accuracy of the following $K_t/V$ prediction equation:

$$K_t/V = -\ln(R - GFAC \times T_{hours}) + (4 - 3.5 \times R) \times 0.55 \times \frac{\text{weight loss}}{V},$$

where $R = \text{post-dialysis/pre-dialysis blood urea nitrogen}$ and GFAC, originally set to 0.008 for a 3/week schedule (Daugirdas, J Am Soc Nephrol 1993), is a factor that adjusts for urea generation.

Results. With the above equation, there was <0.1% mean error in predicted treatment $K_t/V$ for 3/week patients, but mean errors were $-5, -9$ and $-13\%$ for the 6/week daily, 4/week nocturnal and 6/week nocturnal patients. Modeling simulations were performed to optimize the GFAC term for dialysis schedule and length of the preceding interdialysis interval (PIDI). After substituting schedule- and interval-optimized GFAC terms, the treatment $K_t/V$ prediction errors were reduced to $-0.81, +0.1$ and $-1.3\%$ for the three frequent dialysis schedules tested.

INTRODUCTION

Current guidelines for hemodialysis adequacy are based on $K_t/V$, the fractional removal of urea per dialysis treatment, expressed as clearance ($K$) multiplied by treatment time ($t$) and divided by the urea distribution volume ($V$). For three treatments per week, the 2006 Kidney Disease Outcomes Quality Initiative (KDOQI) adequacy guidelines recommend a minimum single-pool $K_t/V$ of 1.2 [1]. The European Best Practice Guidelines recommend a minimum equilibrated $K_t/V$ value of 1.2, corresponding to a minimum single-pool $K_t/V$ of 1.35–1.40 [2]. Although the KDOQI guidelines recommend that kinetic modeling be used to measure $K_t/V$, simple explicit formulas such as the urea reduction ratio (URR) and estimation equations for single-pool $K_t/V$ based on the URR, the dialysis session length and fractional volume removal (weight loss divided by $V$ or weight loss divided by body weight) are also allowed by the KDOQI guidelines [1]. In the USA, these simplified formulas continue to be widely used. One commonly used estimating equation for single-pool $K_t/V$ (sp$K_t/V$)
was developed by Daugirdas and will be referred to as the ‘D2’ equation in this report [3]:

\[
\text{spKt/V} = -\ln\left( R - \text{GFAC} \times T_{\text{hours}} \right) + \left( 4 - 3.5 \times R \right) \times 0.55 \times \text{weight loss/\nu, }
\]

where \( R \) is the ratio of post-dialysis blood urea nitrogen (BUN) to pre-dialysis BUN. GFAC (short for ‘g-factor’) is a urea generation term that is multiplied by the session length (in hours) and is subtracted from \( R \) to give an approximate value of what \( R \) would have been in the absence of urea generation during dialysis. The second compound term in the above equation \([(4–3.5 \times R) \times 0.55 \times \text{weight loss/\nu}] \) adjusts for urea removal that occurs as a result of volume contraction and which contributes substantially to \( Kt/V \), but which is not reflected by a change in \( R \). The above ‘D2’ equation, using a GFAC term of 0.008, has been widely used to estimate the dialysis adequacy both clinically, in many research publications examining the impact of delivered \( Kt/V \) on outcome, and in calibrating machine-based measures of \( Kt/V \) to measures derived from the blood measured URR. The D2 equation gives results similar to the two-blood sample method of modeling \( \text{spKt/V} \) described by Depner and Cheer [4] (Daugirdas, Depner, unpublished information) provided that the modeling day is the midweek session after a 2-day preceding interdialysis interval (PIDI). The D2 equation has not been evaluated when blood samples are drawn during the first-of-the-week dialysis after a 3-day PIDI, e.g. on a Monday or Tuesday. More importantly, the D2 equation has not been evaluated for dialysis schedules other than 3/week.

When evaluating adequacy of hemodialysis schedules other than three times per week, the treatment \( Kt/V \) is an insufficient measure of outcome, as it does not reflect the greater or lesser amount of dialysis being delivered due to more or fewer treatments per week. For such schedules, use of the so-called ‘standard \( Kt/V \)’ (std\( Kt/V \)) to ensure minimum adequacy has been recommended [1]. Standard \( Kt/V \) is defined as the modeled urea nitrogen generation rate (g) in mg/min divided by the average pre-dialysis BUN, multiplied by 10 080 and divided by V [5]. Standard \( Kt/V \) (per week) can be calculated directly using urea modeling [5] or it can be estimated from equilibrated treatment \( Kt/V \) [6–8], session length and number of treatment per week by an equation proposed by Leypoldt [9] or by an equation developed by the Frequent Hemodialysis Network (FHN) [10], which accounts for volume changes and gives values for std\( Kt/V \) that are ~7% higher than the Leypoldt estimate. The FHN equation-estimated std\( Kt/V \) closely matches the value derived from the formal two-pool kinetic modeling [10].

For other than 3/week dialysis schedules, KDOQI proposed a minimum value of 2.0 for std\( Kt/V \) estimated using the Leypoldt equation [1], which translates into a minimum value of 2.14 for std\( Kt/V \) calculated by formal two-pool modeling or estimated using the FHN equation [10]. Before a non-modeling approach to computing std\( Kt/V \) can be accepted, the validity of the estimating equation-based approach to calculate treatment \( Kt/V \) for these novel dialysis schedules needs to be validated. This is the purpose of the present paper.

**MATERIALS AND METHODS**

Preliminary work showed that the D2 equation predicted \( \text{spKt/V} \) for 3/week schedules quite well but that \( \text{spKt/V} \) was substantially underestimated when dialysis was given more often than three times per week. To better understand the problem, we simulated dialysis schedules where two to seven treatments were being given per week to patients with a urea distribution volume (V) of 35 L and urea generation rates, g of 3, 5 or 7 mg/min. Session lengths ranged from 120 to 420 min, and dialyzer urea clearances ranged from 160 to 300 mL/min. For these simulations, the two-pool model used was based on two storage pools for urea, the proximal pool being one-third of the total distribution volume (V) and the distal pool being two-thirds of V [11]. All fluid removed or added to the body during the week was assumed to be added to the proximal urea pool (presumed extracellular water space). The intercompartmental transfer clearance between these two pools was assumed to vary with body size and was set so it would be equal in milliliters per minute to 16 times V measured in liters [11]. Rather than starting with values of pre- and post-dialysis BUN, we began with input values for V (35 L), g and the weekly fluid removal rate (0.1–14 L/week). We then used numerical integration methods to generate minute-by-minute weekly BUN concentration profiles over sequential weeks until the profiles stabilized. From the weekly concentration BUN profile, one could then retrieve projected values for pre- and post-dialysis BUN for every dialysis day of the week. These projected BUN values were then used to compute single-pool \( Kt/V \) (sp\( Kt/V \)) using the Depner and Cheer modeling approach [4]. We then compared these modeled values of sp\( Kt/V \) with the D2 estimate of sp\( Kt/V \) using both the originally proposed ‘g-factor’ or GFAC value of 0.008 and new values for GFAC optimized by number of treatments per week and length of the PIDI in days, where PIDI was calculated from the beginning of the preceding dialysis to the start time of the modeled session.

Finally, we tested the ability of both the original D2 equation and the revised equation using the schedule- and PIDI-optimized values for GFAC to predict sp\( Kt/V \) in subjects enrolled in the FHN Trials [12, 13] who were undergoing dialysis three, four or six times per week. The two FHN trials examined intermediate outcomes after changing from conventional 3/week dialysis to 6/week schedules. In the FHN Daily Trial [12], the average 6/week session length was 150 min, whereas in the Nocturnal Trial [13], it was 390 min. Data were also available in patients undergoing nocturnal dialysis four times per week, as not all patients randomized to 6/week nocturnal treatment were compliant with the assigned number of treatments per week. For these analyses, we excluded patients with residual renal function >2.0 mL/min and assumed residual renal function to be zero.

**RESULTS**

Optimized values for GFAC based on number of treatments per week for different PIDI are shown in Table 1. As shown in Figure 1, GFAC was primarily dependent on PIDI and could
be roughly estimated as $0.0174$ divided by PIDI in days. Dialysis frequency (F, number of treatments per week) had a lesser impact, but the optimum value for GFAC was obtained after adjusting for both PIDI and F.

Comparison of D2-predicted treatment $\frac{Kt}{V}$ with modeled $\frac{Kt}{V}$ in the FHN patients studied is shown in Table 2. For 541 ‘conventional’ dialysis sessions delivered three times per week, the D2 equation using a GFAC value of $0.008$ predicted the modeled $\frac{Kt}{V}$ with a mean error of only $0.067 \pm 1.0\%$. However, the unmodified D2 equation substantially underestimated $\frac{Kt}{V}$ for 6/week ‘daily’ dialysis (Table 2), where the mean error was $-5.0 \pm 1.9\%$, and for 6/week long nocturnal dialysis, where the mean error was $-13 \pm 8.8\%$. In patients in the FHN Nocturnal trial dialyzed only four times per week, the unmodified D2 equation also underestimated $\frac{Kt}{V}$ with a mean error of $-8.9 \pm 9.3\%$. As shown in Table 2, changing GFAC from $0.008$ to the frequency and PIDI-specific coefficients shown in Table 1 markedly improved the $\frac{Kt}{V}$ estimate. When using the simpler, frequency-independent PIDI-corrected value of GFAC (GFAC = $0.0174$/PIDI), the errors in $\frac{Kt}{V}$ were only slightly higher for the 4/week and 6/week schedules tested (Table 2).

Figure 2 shows the URR plotted against the percent error in treatment $\frac{Kt}{V}$ calculated according to the D2 equation using the schedule- and PIDI-optimized GFAC values shown in Table 1. The errors were under $10\%$ except for two outliers in the 6/week nocturnal group. In these two cases, the URR values were $83$ and $85\%$, respectively, and they had a very low ratio of modeled to anthropometric (Watson) volume, $0.32$ and $0.37$, respectively (normally this ratio should be $\sim 0.9$). The modeled $\frac{Kt}{V}$ values in these two outlier patients were quite high, $3.97$ and $3.89$, respectively. Previous modeling work showed that the D2 approach to calculating $\frac{Kt}{V}$ begins to overestimate $\frac{Kt}{V}$ markedly at very high values of URR, e.g. when URR $>88\%$. These outliers suggest that for long nocturnal dialysis, D2 should not be used to estimate $\frac{Kt}{V}$ when the URR is $>82\%$.

A third level of GFAC optimization might be to take into account the dialysis session length. Modeling suggested that for

---

**Table 1. Simulation-derived values for the GFAC term**

<table>
<thead>
<tr>
<th>PIDI (days)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/week</td>
<td>0.0055</td>
<td>0.0045</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/week</td>
<td>0.0080</td>
<td>0.0060</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/week</td>
<td>0.0155</td>
<td>0.0090</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5/week</td>
<td>0.0175</td>
<td>0.0095</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/week</td>
<td>0.0175</td>
<td>0.0095</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7/week</td>
<td>0.0175</td>
<td>0.0175</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*When dialysis session length >300 min, a slightly higher (e.g. +0.0010) GFAC value gave better results (with PIDI values of 1 or 2).*

---

**Table 2. Modeled versus estimated $\frac{Kt}{V}$**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>3/wk_conv (nd = 541)</th>
<th>6/wk_day (nd = 687)</th>
<th>6/wk noc (nd = 120)</th>
<th>4/wk noc (nd = 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kd (mL/min)</td>
<td>221 ± 33</td>
<td>147 ± 21</td>
<td>419 ± 37</td>
<td>430 ± 56</td>
</tr>
<tr>
<td>Modeled two-pool V (L)</td>
<td>37.3 ± 9.6</td>
<td>36.3 ± 9.5</td>
<td>41.0 ± 14</td>
<td>38.9 ± 15</td>
</tr>
<tr>
<td>Modeled $\frac{Kt}{V}$</td>
<td>1.59 ± 0.29</td>
<td>1.20 ± 0.22</td>
<td>1.87 ± 0.64</td>
<td>2.24 ± 0.80</td>
</tr>
<tr>
<td>Estimated $\frac{Kt}{V}$ GFAC = 0.008</td>
<td>1.59 ± 0.29</td>
<td>1.14 ± 0.22</td>
<td>1.60 ± 0.50</td>
<td>2.01 ± 0.66</td>
</tr>
<tr>
<td>Estimated $\frac{Kt}{V}$ GFAC adjusted for both F and PIDI</td>
<td>1.58 ± 0.29</td>
<td>1.19 ± 0.26</td>
<td>1.87 ± 0.73</td>
<td>2.25 ± 0.82</td>
</tr>
<tr>
<td>Estimated $\frac{Kt}{V}$ GFAC = 0.0174/ PIDI</td>
<td>1.59 ± 0.30</td>
<td>1.19 ± 0.22</td>
<td>1.85 ± 0.72</td>
<td>2.33 ± 0.92</td>
</tr>
</tbody>
</table>

*Adjustment for F (number of treatments per week) and PIDI (days): GFAC = 0.008 (3/2); 0.006 (3/3); 0.0095 (6/2); 0.0175 (6/1); 0.009 (4/2); 0.0155 (4/1). Of the 6/week dialyses, 535 had PIDI = 1 and 272 PIDI = 2; of the 3/week dialyses, 387 had PIDI = 2 and 154 PIDI = 3; of the 4/week dialyses, 8 had PIDI = 1 and 10 had PIDI = 2; nd, no. of dialyses; conv, conventional; noc, nocturnal.*
5–7/week dialysis, when dialysis session length was >300 min, the optimum GFAC values were slightly higher (by 0.0010) than those shown in Table 1. Accordingly, the optimum GFAC values for subjects undergoing 6/week long nocturnal dialysis would be 0.0185 and 0.0105 when the PIDI are 1 and 2 days, respectively.

In the Supplemental material, in Figure 3A through D, we plot the percent error in spKt/V against weight loss, while using schedule- and PIDI-optimized values for GFAC as per Table 1. These results corroborated findings from simulations that the volume contraction term of the original D2 equation would be unlikely to benefit from further adjustment based on dialysis frequency or PIDI.

**DISCUSSION**

Our results suggest that the accuracy of the original D2 equation can be improved for dialysis schedules other than 3/week by applying the frequency and PIDI-dependent GFAC values shown in Table 1. Acceptable accuracy can also be obtained by approximating GFAC as 0.0174/PIDI. The procedure to estimate stdKt/V would be as follows: (i) compute estimated treatment spKt/V using the D2 equation with schedule and frequency (and perhaps session length) optimized values for GFAC, (ii) compute eKt/V from spKt/V and dialysis session length using the optimized Tattersall equation [6, 1] and (iii) from eKt/V, session length and treatments per week, compute stdKt/V using the FHN equation [10]. It should be noted that these improvements to the D2 equation were determined for typical hemodialysis prescriptions during the FHN trial and the accuracy of these improvements may not apply if the prescription deviates substantially from those evaluated here. When more exact values are required, values for stdKt/V can be calculated directly using formal kinetic modeling [11].

**SUPPLEMENTARY DATA**

Supplementary data are available online at [http://ndt.oxfordjournals.org](http://ndt.oxfordjournals.org).

**ACKNOWLEDGEMENTS**

Supported by the National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases, the Center for Medicare and Medical Services and the NIH Research Foundation. Contributors to the NIH Foundation in support of the FHN trials included Amgen, Baxter Healthcare Corporation and Dialysis Clinics, Inc. (DCI). Additional support was provided by DaVita, DCI, Fresenius Medical Care, Renal Advantage, Renal Research Institute and Satellite Healthcare. A list of members of the FHN Trial Group for each study has been published. See references 12 and 13.

**CONFLICT OF INTEREST STATEMENT**

JK Leypoldt and A Akonur are employees of Baxter Healthcare Corporation.

Diverse effects of interdialytic intervals on central wave augmentation in haemodialysis patients

Panagiotis I. Georgianos1, Pantelis A. Sarafidis1, Anna-Bettina Haidich2, Antonios Karpetas3, Dimitrios Stamatiadis3, Pavlos Nikolaidis1 and Anastasios N. Lasaridis1

Correspondence and offprint requests to: Panagiotis I. Georgianos; E-mail: pigeoriganos@yahoo.gr

Keywords: augmentation index, arterial stiffness, haemodialysis, interdialytic interval, pulse wave velocity

Background. Increased arterial stiffness is a common finding and independent predictor of mortality in end-stage renal disease (ESRD) patients. A long interdialytic interval was associated with increased risk of cardiovascular death in patients receiving conventional haemodialysis (HD). This is the first study to examine the effects of a long (3-day) versus short (2-day) interdialytic period on arterial elasticity in HD patients.